.Nature Medication, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for inclusion of patients with MASLD and dimension of liver end results in cardio-- renal-- metabolic trials, when data advise mechanistically probable advantages and also scientific protection-- as well as details points to consider for trial style as well as regulative approval.